医学
套细胞淋巴瘤
阿替唑单抗
美罗华
奥比努图库单抗
内科学
巨球蛋白血症
肿瘤科
临床研究阶段
不利影响
华登氏巨球蛋白血症
淋巴浆细胞淋巴瘤
胃肠病学
淋巴瘤
临床试验
免疫疗法
癌症
多发性骨髓瘤
彭布罗利珠单抗
作者
Panayiotis Panayiotidis,Gayane Tumyan,Catherine Thiéblemont,В. В. Птушкин,Ana Marín‐Niebla,Ramón García‐Sanz,Steven Le Gouill,Anastasios Stathis,Alessia Bottos,Habib Hamidi,Pablo Katz,Thomas Perretti,Jenna C. Willis,Christian Buske
标识
DOI:10.1080/10428194.2021.2015765
摘要
We report efficacy, safety and biomarker data from a phase-II study evaluating atezolizumab (eight 21-day cycle as induction therapy) in combination with obinutuzumab in patients with relapsed/refractory mantle cell lymphoma (MCL, n = 30) or Waldenström's macroglobulinemia (WM, n = 4), and in combination with rituximab in patients with marginal zone lymphoma (MZL, n = 21). All patients received atezolizumab monotherapy as maintenance for ≤10 cycles. Objective response rates at end of induction were 16.7% (MCL) and 42.9% (MZL), with no responses in WM. Median duration of response was 6.8 months (range 5.7-not estimable) for MCL and not reached for MZL. Treatment-emergent adverse events (TEAEs) occurred in 93.3%, 95.2% and 100% of MCL, MZL and WM patients, respectively. One fatal TEAE (pneumonia) occurred in each of the MCL and MZL groups. Biomarker analysis highlighted the importance of characterizing the immune environment to optimize efficacy of immunotherapy regimens.Trial registration details: EudraCT: 2016-003579-22.
科研通智能强力驱动
Strongly Powered by AbleSci AI